

LET YOUR PATIENTS
WAKE UP TO
NEW POSSIBILITIES

RYBELSUS[®]
semaglutide tablets

A GAME CHANGER. A LIFE CHANGER.

PRODUCT DOSSIER

For adults with type 2 diabetes

• A dosing guide to get patients started on once-daily oral RYBELSUS

For the use only of registered medical practitioners or a hospital or a laboratory



Apis Bull and Rybelsus[®] are registered trademarks of Novo Nordisk A/S.

RYBELSUS[®]
semaglutide tablets

This content is strictly for healthcare professionals practicing in India.

RYBELSUS[®]
semaglutide tablets





INDEX

1. India's Unmet Needs	01
2. Multiple Benefits of GLP-1 RAs	03
3. Oral Delivery of Peptides	05
4. SNAC makes all the difference	06
5. Innovation of Oral semaglutide	08
6. Efficacy and safety parameters	09

Summary

RYBELSUS® is used to treat adults with poorly controlled diabetes mellitus type 2 (DMT2) used in combination with other antidiabetic agents, diet and exercise.²⁴

“Oral semaglutide may offer a practical and effective means of managing people living with T2D who require treatment intensification, and may change the paradigm of care in the primary care setting”. Seidu et al., Prim Care Diabetes (2021)

RYBELSUS®
semaglutide tablets
A GAME CHANGER. A LIFE CHANGER.

LET YOUR PATIENTS
**WAKE UP TO
NEW POSSIBILITIES**

**World's first
Oral GLP-1 RA1**

**Significantly greater HbA_{1c}
reduction of 1.5%**

**Consistent CV outcomes
with the GLP-1 RA class**

**Sustained weight loss of
~5 kgs**

RYBELSUS®
EMA human medicines
highlight 2020
Endocrinology

RYBELSUS®
Galien Award
Germany 2020
Primary Care


*EMA. HUMAN MEDICINES HIGHLIGHTS 2020. Stand: 21.1.2021. Verfügbar unter: <https://www.ema.europa.eu/en/news/human-medicines-highlights-2020>.

**Arztezeitung. RYBELSUS®: Diabetes- Therapie mit oralem GLP-1-Analogen. Verfügbar auf: <https://www.aerztezeitung.de/Specials/Rybelus-Diabetes-Therapie-mit-oralem-GLP-1-Analogen-413978.html>, zuletzt abgerufen: 03/2021.



India's Unmet Needs

India currently has a total adult population with diabetes of **over 77 million** with a prevalence of diabetes in adults at **8.9%**. **463 million people** have diabetes in the world and 88 million people in the SEA Region; by 2045 this will rise to 153 million. With such a high prevalence of diabetes in India¹, it is imperative that the healthcare sector is equipped to deliver quality care for people with diabetes and its management.



As per the rule of halves, only **18.22 million patients** are treated (~25% of people with diabetes). **70%** of the people with diabetes **do not achieve the recommended treatment target of an HbA_{1c} level below 7%**.² Diabetes is a progressive disease characterised by impaired beta cell function, and reduced insulin sensitivity and secretion.

Moreover, obesity is a common co-morbidity in subjects with type-2 diabetes (60-90% of patients diagnosed). Additional weight gain as a consequence of treatment with SU's or insulin for example, can reduce patients' quality of life and hinder adherence to treatment. Obesity is also an independent risk factor for cardiovascular disease, further compromising patient outcomes.⁵

Over time, glycaemic control deteriorates and exacerbates the risk of patients experiencing micro- and macrovascular complications.

The greatest challenge in treating patients with type-2 diabetes is optimising therapy to address the current unmet needs: Improve glycaemic control without compromising safety i.e. Hypoglycaemia




Although there is an abundance of treatment options and guidelines available for the management of type-2 diabetes, they are unable to avert the natural progression of the disease and sustain glycaemic control in the long term. Furthermore, currently available treatment options are often associated with hypoglycaemia and weight gain.^{3,4} Such adverse effects can have detrimental health implications for the patient. For example, hypoglycaemia can be an unpleasant side-effect of anti-diabetic therapy which can compromise patient adherence to treatment, and serious hypoglycaemic events, left untreated, can lead to a loss of consciousness, brain damage or even death.

Multiple Benefits of GLP-1 RAs

Pharmacologically, long-acting GLP-1 receptor agonists (GLP-1RAs) exhibit glucoregulatory functions via multiple mechanisms, namely, stimulation of insulin release in a glucose-dependent manner, suppression of glucagon activity during hyperglycemia, and a minor delay of gastric emptying resulting in slower glucose absorption⁶.


In addition, GLP-1 promotes satiety and reduces energy intake by virtue of its neurotransmitter role in brainstem-hypothalamus pathways signalling satiety and some long-acting GLP-1RAs including semaglutide have shown cardiovascular risk reduction⁶.

Effects of GLP-1 RAs on various tissues



GLP-1 RAs target multiple pathophysiological defects of T2DM

GLP-1 RAs directly or indirectly target nearly all of the eight core pathophysiological defects of T2DM (ominous octet), more than any other class of antihyperglycemic medication





Oral Delivery of Peptides

Medicines like peptides are effective but until recently could only be delivered by injection. Many patients prefer pills over injections, hence posing a challenge to patients, in initiating and adherence to therapy.

Oral administration of therapeutic peptides is hindered by poor absorption across the gastrointestinal barrier and extensive degradation by proteolytic enzymes.

The inherent physicochemical properties of peptides (high molecular weight, enzymatically labile, hydrophilicity, and low permeability) have hampered attempts to deliver peptides such as GLP-1 via the oral route.⁷

This is mainly because the vast majority of peptides evaluated for oral delivery have been ill-equipped to surmount the challenges presented by the hostile environment of the GIT, which is designed to degrade proteins and peptides ingested in food to di- and tripeptides before absorption in the small intestine.

Thus, subtherapeutic exposure and high inter- and intraindividual variability have resulted. In addition, many peptides obtain protraction from the subcutaneous administration site while having a shorter intravenous t_{1/2}, making the duration of action unsuitably short if given orally.



GI-tract degrades and digests peptides^{8,25,26,27}



Low permeability through the intestinal cell wall²⁵⁻²⁶




Pairing the right molecule with the right absorption enhancer⁸

In line with this, recent advancements in fatty acid acylation-based protraction technology have provided the possibility of achieving extended plasma half-lives (t_{1/2}) without increasing molecular size, leading to the discovery of semaglutide, a GLP-1 analogue with a t_{1/2} of ~1 week in humans.⁸

The need of the hour was to find a way to make GLP-1 protein withstand the digestive functions, preventing GLP-1 molecule from breaking down in the stomach required right pairing with the right absorption enhancer.

After a significant effort, there was a breakthrough with an enhancer called SNAC, which protects semaglutide from breaking down in the stomach.



SNAC ABSORPTION ENHANCER
protects semaglutide from breaking down in the stomach

8. Knudsen and Lau. Front Endocrinol. 2019;10:155;doi: 10.3389/fendo.2019.00155. 25. Antza et al. Drug Design Development and Therapy. 2019;13:2985-2996. 26. Brayden and Alonso. Adv Drug Deliv Rev. 2016 Nov 15;106(Pt B):193-195. 27. Buckley et al. Sci Transl Med. 2018;10: eaar7047.



SNAC makes all the difference

SNAC is Sodium N-[8-(2-hydroxybenzoyl) aminocaprylate]


Semaglutide has a high degree of homology (~94%) with the human GLP-1 molecule with the three key changes in the molecule.⁹

SNAC is an absorption enhancer with the ability to increase the absorption of semaglutide across the GI epithelium. SNAC interacts with the gastric cell membrane and secures transcellular absorption of semaglutide.¹⁰

Unlike most drugs, the co-formulation of semaglutide & SNAC is absorbed in the stomach rather than in the intestine. SNAC buffers the local pH of the stomach to protect against enzymatic degradation and facilitate transepithelial absorption via the transcellular route. Thus, SNAC protects against enzymatic degradation via local buffering actions and only transiently enhances absorption.

Co-formulation of semaglutide with an absorption enhancer is necessary to achieve adequate bioavailability of oral administration.¹¹

The mechanism of absorption is shown to be compound specific, transcellular, and without any evidence of effect on tight junctions. This might be the game changer in management of T2DM.




Sources: 1. Kalra S, Sahay R. Diabetes Ther. 2020;11(9):1965-1982. 2. Bucheit JD, Pamulapati LG, Carter N, et al. Diabetes Technol Ther. 2020;22(1):10-18.

Innovation of Oral semaglutide

Oral semaglutide developed by Novo Nordisk, is the first oral Glucagon Like Peptide-1 Receptor Agonist (GLP-1 RA) for the treatment of type 2 diabetes mellitus. It is a result of 15 long years of ceaseless efforts to make semaglutide available in a pill. Strong beliefs, collaborations and sheer dedication of the scientists, to help improve the management of type 2 diabetes led to this breakthrough achievement.

SNAC is Sodium N-[8-(2-hydroxybenzoyl) aminocaprylate]



Orally administered semaglutide is co-formulated with an absorption enhancer, SNAC (Sodium N-[8-(2-hydroxybenzoyl) Amino] Caprylate):

- Allows Rybelsus® to be absorbed from the stomach
- Promotes absorption across the gastric mucosa
- Protects Rybelsus® from breakdown by gastric enzymes

The pharmacological innovation by RYBELSUS®

The co-formulation with the absorption enhancer SNAC enables the gastrointestinal ingestion of Semaglutide

- **SNAC protects against semaglutide gastrointestinal degradation, by increasing the pH locally.**
- **SNAC promotes the transcellular Absorption of Semaglutide via the gastric epithelium.**
- **With SNAC there is an estimated increase in Oral Semaglutide Bioavailability reached by almost a power of ten.**




- White oval tablet for oral use Administration. (All dosages have the same size of 13.5 × 7.5 mm).²⁴
- Active ingredient: Semaglutidum (3 mg, 7 mg or 14 mg per tablet).



With the recommended maintenance dose, of RYBELSUS®, comparable plasma level is reached as with subcutaneous semaglutide.

Subcutaneous semaglutide is not approved in India

Adapted from Seidu et al. 2021





Efficacy and safety parameters

Clinical trials¹²⁻¹⁹

- PIONEER – the largest ever phase 3 clinical trials were initiated in 2016, with 9,543 participants.
- 9543 subjects enrolled into the study and 5907 were exposed to oral semaglutide 8 global trials and 2 trials in Japanese population. Overall, ten PIONEER efficacy and safety trials as well as cardiovascular safety trial were completed with encouraging results.

Diet and exercise	OAD	Insulin users	Japan
PIONEER 1	PIONEER 2	PIONEER 8	PIONEER 9
vs placebo (Diet and exercise)	vs SGLT2i (Met)	Add-on to insulin (Insulin ± Met)	vs GLP-1RA/placebo (Diet and exercise)
	PIONEER 3	Special Populations	
	vs DPP-4i (1-2 OADs: Met ± SU)	PIONEER 5	PIONEER 10
	PIONEER 4	Renal impairment (± Met, ± SU, or ± insulin)	vs GLP-1RA (1 OAD: SU/TZD/ α-GI/SGLT2i)
	vs GLP-1RA/placebo (1-2 OADs: Met ± SGLT2i)	PIONEER 6	
	PIONEER 7	CV safety (Standard of care)	
	Flexible dose adjustment vs DPP-4i with extension (1-2 OADs: Met, SU, TZD, SGLT2i)		

CV, cardiovascular; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; Met, metformin; OAD, oral anti-diabetes drug; SGLT2i, sodium glucose co-transporter-2 inhibitor; SU, sulphonylurea; TZD, thiazolidinedione.

HbA_{1c} reduction¹²⁻¹⁹



- HbA_{1c} reduction of 1.3 and 1.5 % was seen in 7 mg and 14 mg Oral semaglutide doses respectively at the end of 26 weeks as compared to placebo which was statistically significant.

Proportion of patients achieving HbA_{1c} targets¹²⁻¹⁹

- Up to 80% of the patients achieved HbA_{1c} <7.0%¹². The odds of achieving HbA_{1c} <7.0% were statistically significantly greater with oral semaglutide than with sitagliptin, empagliflozin and placebo. Up to 68% of the patients achieved HbA_{1c} ≤6.5%. The odds of achieving HbA_{1c} ≤6.5% were statistically significantly greater with oral semaglutide than with sitagliptin, empagliflozin, liraglutide and placebo.
- Up to 73% of the patients achieved HbA_{1c} <7.0% (7 out of 10 patients) without severe or blood glucose confirmed symptomatic hypoglycaemia and without weight gain. The odds of achieving the target were statistically significantly greater with oral semaglutide than with placebo, sitagliptin, empagliflozin and liraglutide.

Body weight¹²⁻¹⁹

- Oral semaglutide 14 mg was associated with sustained weight reduction over the duration of the trials (up to -5.0 kg from baseline to final time point). Oral semaglutide 14 mg used as monotherapy or in combination with 1-2 glucose-lowering agents resulted in statistically significant reduction in body weight compared with placebo, sitagliptin, liraglutide and empagliflozin(EoT).¹³
- Up to 49% and 18% of patients achieved a weight loss of ≥5% and ≥10%, respectively. The odds of achieving a weight loss of ≥5% and ≥10% were statistically significantly greater with oral semaglutide 14 mg than with placebo, sitagliptin and liraglutide.¹⁴



Efficacy of oral semaglutide according to baseline HbA_{1c}

Oral Semaglutide provides unsurpassed HbA_{1c} reduction in T2D patients with baseline HbA_{1c} >9%
Up to **-2.6%**

Trial	HbA _{1c} (%) at baseline	Estimated mean change from baseline in HbA _{1c} (%-points)					
		Oral semaglutide			Comparator(s)		
		3 mg	7 mg	14 mg	Flex	Pbo	Active
PIONEER 1 (diet and exercise)	≤8 (n=409)	-0.5	-1.1	-1.2	-	0.0	-
	>8-≤9 (n=244)	-1.1	-1.6	-1.8	-	-0.1	-
	>9 (n=50)	-1.5	-1.8	-2.6	-	-0.6	-
PIONEER 2 (vs empagliflozin 25 mg)	≤8 (n=457)	-	-	-1.0	-	-	-0.5
	>8-≤9 (n=211)	-	-	-1.8	-	-	-1.1
	>9 (n=153)	-	-	-2.0	-	-	-1.7
PIONEER 3 (vs sitagliptin 100 mg)	≤8 (n=850)	-0.3	-0.6	-0.9	-	-	-0.5
	>8-≤9 (n=593)	-0.5	-1.1	-1.5	-	-	-0.8
	>9 (n=420)	-1.0	-1.9	-2.2	-	-	-1.4
PIONEER 4 (vs liraglutide 1.8 mg and pbo)	≤8 (n=403)	-	-	-1.0	-	-0.0	-0.8
	>8-≤9 (n=248)	-	-	-1.6	-	-0.1	-1.4
	>9 (n=60)	-	-	-2.2	-	-0.1	-2.0
PIONEER 5 (renal impairment)	≤8 (n=188)	-	-	-0.8	-	0.1	-
	>8-≤9 (n=108)	-	-	-1.5	-	-0.3	-
	>9 (n=28)	-	-	-2.1	-	-0.4	-
PIONEER 7 (flex vs sitagliptin 100 mg)	≤8 (n=201)	-	-	-	-1.0	-	-0.5
	>8-≤9 (n=246)	-	-	-	-1.5	-	-0.7
	>9 (n=57)	-	-	-	-2.0	-	-1.5
PIONEER 8 (added-on to insulin)	≤8 (n=329)	-0.3	-0.6	-1.0	-	0.2	-
	>8-≤9 (n=296)	-0.7	-1.2	-1.6	-	-0.2	-
	>9 (n=106)	-1.2	-1.8	-2.3	-	-0.1	-

Mixed model for repeated measures analysis with treatment, region, stratification factors and interaction between them, as well as baseline HbA_{1c} group and interaction between treatment and baseline HbA_{1c} groups as factors, and baseline value of dependent variable as covariate. -, not investigated in trial; flex, flexible dose adjustment; pbo, placebo.



Fasting plasma glucose

- Treatment with oral semaglutide reduced FPG by up to 45 mg/dL (2.5 mmol/L) across the phase 3a trials. The reductions were sustained through week 78.



Beta-cell function and insulin resistance

- Beta-cell function measured by homeostasis model assessment for beta-cell function (HOMA-B) and insulin resistance measured by homeostasis model assessment for insulin resistance (HOMA-IR) overall improved with oral semaglutide 7 mg and 14 mg.



Cardiovascular risk reduction

- Consistent cardiovascular risk reduction was shown in SUSTAIN 6 and PIONEER 6, supported by an analysis including data from both trials. In this analysis, patients treated with semaglutide had a statistically significant lower risk of the first occurrence of MACE compared to placebo. The estimated HR was 0.76 [0.62; 0.92]95% CI.



Cardiovascular risk factors

- Treatment with oral semaglutide reduced systolic blood pressure by up to 7 mmHg and C-reactive protein concentrations by up to 35% and improved the fasting lipid profile (e.g. triglycerides reduction of up to around 13%).



Pharmacokinetics

- The absorption of semaglutide predominantly occurs in the stomach. The estimated absolute bioavailability of semaglutide is approximately 1% following oral administration. The primary excretion routes of semaglutide-related material are via the urine and faeces. Approximately 3% of the absorbed dose is excreted as intact semaglutide via the urine, with an elimination half-life of approximately 1 week.

Biotransformation/Metabolism

- Semaglutide is metabolised through proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid sidechain. The enzyme neutral endopeptidase (NEP) is expected to be involved in the metabolism of semaglutide.
- SNAC metabolism: As with other fatty acid derivatives, SNAC is metabolized via β -oxidation and glucuronidation and eliminated mainly via urine.

Summary of safety profile

In 10 phase 3a trials, 5,707 patients were exposed to oral semaglutide alone or in combination with other glucose-lowering medicinal products. The duration of the treatment ranged from 26 weeks to 78 weeks. The most frequently reported adverse reactions in clinical trials were gastrointestinal disorders, including nausea (Up to 80% did not experience nausea), diarrhoea and vomiting. In general, these reactions were mild or moderate in severity and of short duration.

Posology and method of administration²⁰

In 10 phase 3a trials, 5,707 patients were exposed to oral semaglutide alone or in combination with other glucose-lowering medicinal products. The duration of the treatment ranged from 26 weeks to 78 weeks. The most frequently reported adverse reactions in clinical trials were gastrointestinal disorders, including nausea (Up to 80% did not experience nausea), diarrhoea and vomiting. In general, these reactions were mild or moderate in severity and of short duration.

Posology

- The starting dose of oral semaglutide is 3 mg once daily. After 1 month, the dose should be increased to a maintenance dose of 7 mg once daily. If additional benefits are needed after at least one month on the 7 mg dose, the dose can be increased to a maintenance dose of 14 mg once daily.

Therapeutic indication

Semaglutide is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus

- As monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- In combination with other medicinal products for the treatment of diabetes.

When oral semaglutide is used in combination with metformin and/or a sodium-glucose co-transporter-2 inhibitor (SGLT2i) or thiazolidinedione, the current dose of metformin and/or SGLT2i/thiazolidinedione can be continued. When oral semaglutide is used in combination with a sulfonylurea or insulin, a reduction in the dose of sulfonylurea or insulin should be considered to reduce the risk of hypoglycaemia.

Missed dose

- If a dose is missed, the missed dose should be skipped, and the next dose should be taken the following day.

Special Population

- Elderly (≥ 65 years old)
- No dose adjustment is required based on age.

Gender

- No dose adjustment is required based on gender.

Race and ethnicity

- No dose adjustment is required based on race and ethnicity.



Children and adolescents

- The safety and efficacy of Oral semaglutide in children and adolescents below 18 years have not been studied.



Pregnancy and Breastfeeding

- There are limited data from the use of semaglutide in pregnant women. Therefore, Oral semaglutide should not be used during pregnancy. Oral semaglutide should not be used during breast-feeding.



Renal and hepatic impairment

- Renal and hepatic impairment did not impact the pharmacokinetics of semaglutide in a clinically relevant manner.

Method of administration²⁴

- Oral semaglutide is a tablet for once-daily oral use.
- Oral semaglutide should be taken on an empty stomach. Oral semaglutide should be swallowed whole with up to half a glass of water equivalent to 120 ml. Do not split, crush or chew the tablet. Wait at least **30 minutes** before the first meal or drink of the day or taking other oral medicinal products. Waiting less than 30 minutes may decrease the absorption of semaglutide.



Take on an empty stomach upon waking



Swallow tablet whole with a sip of water (up to 120 mL)



Wait at least 30 minutes before eating, drinking, or taking any other oral medication

Contraindications²⁴

Hypersensitivity to the active substance or to any of the excipients listed in section 8.0 Pharmaceutical Particulars

Special warnings and precautions for use²⁴

Oral semaglutide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

Gastrointestinal effects

Use of GLP-1 receptor agonists may be associated with gastrointestinal adverse reactions that can cause dehydration, which in rare cases can lead to a deterioration of renal function.

Acute pancreatitis

Acute pancreatitis has been observed with the use of GLP-1 receptor agonists. Patients should be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, Oral semaglutide should be discontinued; if confirmed, Oral semaglutide should not be restarted. Caution should be exercised in patients with a history of pancreatitis. In the absence of other signs and symptoms of acute pancreatitis, elevations in pancreatic enzymes alone are not predictive of acute pancreatitis.

Hypoglycaemia

Insulin and sulfonylurea are known to cause hypoglycaemia. Patients treated with Oral semaglutide in combination with a sulfonylurea or insulin may have an increased risk of hypoglycaemia. The risk of hypoglycaemia can be lowered by reducing the dose of sulfonylurea or insulin when initiating treatment with Oral semaglutide.

Diabetic retinopathy

Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Long-term glycaemic control decreases the risk of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for worsening and treated according to clinical guidelines.

Heart failure

There is no therapeutic experience in patients with congestive heart failure New York Heart Association (NYHA) class IV.

Drugs interactions

- In vitro studies have shown very low potential for semaglutide to inhibit or induce CYP enzymes, and to inhibit drug transporters.
- Semaglutide delays gastric emptying which may influence the absorption of other oral medicinal products.

Effects of oral semaglutide on other medicinal products

- Total exposure (AUC) of thyroxine (adjusted for endogenous levels) was increased by 33% following administration of a single dose of levothyroxine. Maximum exposure (C_{max}) was unchanged. Monitoring of thyroid parameters should be considered when treating patients with semaglutide at the same time as levothyroxine.
- No clinically relevant change in AUC or C_{max} of warfarin, digoxin, oral contraceptives (containing ethinylestradiol and levonorgestrel), metformin, furosemide or rosuvastatin was observed when concurrently administered with semaglutide.

Effects of other medicinal products on semaglutide

No clinically relevant change in AUC or C_{max} of semaglutide was observed when taken with omeprazole.

Special warnings and precautions for use

Oral semaglutide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

Interaction with food

- Concomitant intake of food reduces the exposure of semaglutide (see section 4.2 Posology and method of administration).
- No clinically relevant drug-drug interaction with semaglutide was observed based on the evaluated medicinal products. Therefore, no dose adjustment is required for medicinal products when taken with Oral semaglutide.

Advantages of Oral semaglutide¹²⁻²³



Oral semaglutide reduces HbA_{1c} in a clinically relevant and dose-dependent manner



The risk of hypoglycaemia is low with oral semaglutide when used as monotherapy



Clinical inertia and non-adherence seen with injectables pose significant obstacles in reaching glycaemic targets in T2DM, this is overcome with oral semaglutide due to patient convenience and ease of administration



No dose adjustment recommended regardless of renal or hepatic impairment



No dose adjustment recommended in elderly patients



Additional pleiotropic benefits of oral semaglutide is very much needed in multidimensional diseases like type 2 diabetes mellitus

References:

1. International Diabetes Federation, 2021
2. Unnikrishnan R, Anjana RM, Deepa M, et al; ICMR-INDIAB Collaborative Study Group. Glycemic control among individuals with self-reported diabetes in India--the ICMR-INDIAB Study. *Diabetes Technol Ther* 2014; 16:596-603.
3. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med* 2006; 355:2427-43.
4. UKPDS 34, *Lancet* 1998;352:854-65.
5. Jensen KH. Incretin-Based Therapy for Type 2 Diabetes: Overcoming Unmet Needs; *Medicine Update* 2010; Vol. 20; 2 : 15;105-112.
6. Tran KL, Park YI, Pandya S, et al. Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes. *Am Health Drug Benefits*. 2017 Jun;10(4):178-188.
7. Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. *TherDeliv*. 2013;4(11):1443-1467.
8. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. *Front Endocrinol (Lausanne)*. 2019;10:155.
9. Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. *J Clin Pharmacol*. 2015 May;55(5):497-504.
10. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. *Sci Transl Med*. 2018 Nov 14;10(467):eaar7047.
11. Kalra S, Sahay R. A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus. *Diabetes Ther*. 2020;11(9):1965-1982.
12. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. *Diabetes Care*. 2019 Sep;42(9):1724-1732.
13. Rodbard HW, Rosenstock J, Canani LH, et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. *Diabetes Care*. 2019 Dec;42(12):2272-2281.
14. Andersen A, Knop FK, Vilsbøll TA. Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. *Drugs*. 2021; 81:1003-30
15. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. *JAMA*. 2019 Apr 16;321(15):1466-1480.
16. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. *Lancet*. 2019;394:39-50
17. Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomized, phase 3a trial. *Lancet Diabetes Endocrinol*. 2019;7:515-527.
18. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2019;381:841-851.
19. Buse JB, Bode BW, Mertens A, et al. Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial. *BMJ Open Diabetes Res Care*. 2020 Dec;8(2):e001649.
20. Zinman B, Aroda VR, Buse JB, et al. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. *Diabetes Care*. 2019 Dec;42(12):2262-2271.
21. RYBELSUS® summary of product characteristics. Available from: https://ec.europa.eu/health/documents/community-register/2020/20200403147411/anx_147411_en.pdf. Accessed Sep 2021.
22. Granhall C, Søndergaard FL, Thomsen M, et al. Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment. *Clin Pharmacokinet*. 2018 Dec;57(12):1571-1580.
23. Bækdal TA, Thomsen M, Kupčová V, et al. Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment. *J Clin Pharmacol*. 2018 Oct;58(10):1314-1323.
24. Rybelsus® Prescribing information